Promising disease modifying approach to Duchenne muscular dystrophy with Neu-REFIX® Beta 1,3-1,6 glucan* from Japan; the first such clinical report

TOKYO--(Business Wire / Korea Newswire)--Duchenne Muscular Dystrophy (DMD) patients showed signs of disease progress slowing down, after oral consumption of Neu REFIX ß-glucan for 45 days along with routine medications. Clinical improvements published in IBRO Neuroscience reports, might be the world's first such report, wherein, a safe food supplement, mitigated biomarkers of relevance to muscle dysfunction in DMD without side-effects. Increased plasma dystrophin by 32%, indicating improved blood circulation along with muscle strength improvement, is a breakthrough, unraveling the multipronged potential of Neu-REFIX, which also beneficially reconstituted gut microbiome in DMD, gives hope of improving the quality of life and prolonging the life span of DMD patients, opined Dr. Raghavan, the lead author.

Neu-REFIX is an allergen-free ß-glucan, unique for its source, as an exo-polysaccharide from Aureobasidium Pullulans, produced in GMP certified facility in Japan, possessing purity, functionality, water solubility and dosage standardization like a drug, preservable at room temperature, and orally consumable as such or with food. Immune modulatory effects in pre-clinical studies, in healthy Japanese volunteers and Covid-19 patients, showed its potentials as a disease modifying adjuvant, worth undertaking clinical trial in DMD, to yield beneficial effects by controlling inflammation and fibrosis.

Neu-REFIX reduced fibrosis, inflammation, enhanced muscle regeneration, in MDX mice and in a six-month-long clinical study in young boys, improved NSAA, 6MWT and MRC, and these disease modifying potentials were presented in MDA Conference 2023. Neu-REFIX, can be consumed at any stage of DMD, with standard of care medications. Therefore, it’s worth evaluating as a drug-adjuvant because, as reported, Neu-REFIX as a single agent, has helped accomplish, what the current disease modifying treatments, cell-based therapies, and angiogenesis approaches are together, trying to achieve, said Prof. Naoki Yamamoto, a co-researcher.

GNCorp, which spearheaded this accomplishment, has signed a MoU with MAP Healthcare, a subsidiary of SHBK International Holding Group, UAE and intends collaborating with like-minded organizations to validate Neu-REFIX in larger studies. Clinical research in Limb-Girdle Muscle Dystrophy (LGMD), multiple sclerosis and psoriasis are underway, to evaluate Neu-REFIX’s efficacy as a universal immune modulator.

*B-1,3-1,6 glucan is a listed food additive in MHLW, Japan; Not a drug or remedy to any illness. Research findings should not be construed as medical advice. Not GRAS, EFSA certified.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230803923960/en/

Website: https://www.gncorporation.com/

View Korean version of this release

This is a news release distributed by Korea Newswire on behalf of this company.